Molecular markers associated with clinical response to bexarotene therapy in cutaneous T-cell lymphoma

Acta Dermato-Venereologica

Volumn 91, Issue 5, 2011, Pages 568-573

  Ranki, Annamari ^a   Väkevä, Liisa ^a   Sipilä, Laura ^b   Krohn, Kai ^b,c  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b Dermagene Oy   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Bexarotene; Clinical response; Cutaneous T cell lymphoma; Mycosis fungoides; NAV3; Sezary syndrome

Indexed keywords

ANTILIPEMIC AGENT; BEXAROTENE; NEURONAL NAVIGATOR 3; THYROXINE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER REGRESSION; CELLULAR IMMUNITY; CHROMOSOME 12; CLINICAL ARTICLE; COPY NUMBER VARIATION; CUTANEOUS T CELL LYMPHOMA; DISEASE MARKER; DRUG RESPONSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HORMONE SUBSTITUTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPOTHYROIDISM; LETTER; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TETRAPLOIDY; TREATMENT RESPONSE; TUMOR GENE;

EID: 80051988461     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.2340/00015555-1114     Document Type: Letter

References (33)

1. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105: 3768-3785.
2. Karenko L, Hahtola S, Ranki A. Molecular cytogenetics in the study of cutaneous T-cell lymphomas (CTCL). Cytogenet Genome Res 2007; 118: 353-361.
3. Sterry W. Cutaneous T-cell lymphoma: molecular and cytogenetic findings. Oncology (Williston Park) 2007; 21 (Suppl 1): 13-17.
4. Trautinger F, Knobler R, Willemze R, Peris K, Stadler R, Laroche L, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer 2006; 42: 1014-1030.
5. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002; 8: 1234-1240.
6. Song JI, Lango MN, Hwang JD, Drenning SD, Zeng Q, Lamph WW, et al. Abrogation of transforming growth factor-alpha/epidermal growth factor receptor autocrine signaling by an RXR-selective retinoid (LGD1069, Targretin) in head and neck cancer cell lines. Cancer Res 2001; 61: 5919-5925.
7. Miller VA, Benedetti FM, Rigas JR, Verret AL, Pfister DG, Straus D, et al. Initial clinical trial of a selective retinoid X receptor ligand, LGD1069. J Clin Oncol 1997; 15: 790-795.
8. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.
9. Duvic M, Martin AG, Kim Y, Olsen E, Wood GS, Crowley CA, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001; 137: 581-593.
10. Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, et al. Bexarotene therapy for mycosis fungoides and Sézary syndrome. Br J Dermatol 2009; 160: 1299-1307.
11. Karenko L, Hahtola S, Paivinen S, Karhu R, Syrjä S, Kähkönen M, et al. Primary cutaneous T-cell lymphomas show a deletion or translocation affecting NAV3, the human UNC-53 homologue. Cancer Res 2005; 65: 8101-8110.
12. Hahtola S, Burghart E, Jeskanen L, Karenko L, Abdel-Rahman WM, Polzer B, et al. Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma. J Invest Dermatol 2008; 128: 2304-2309.
13. Vermeer MH, van Doorn R, Dijkman R, Mao X, Whittaker S, van Voorst Vader PC, et al. Novel and highly recurrent chromosomal alterations in Sézary syndrome. Cancer Res 2008; 68: 2689-2698.
14. Marty M, Prochazkova M, Laharanne E, Chevret E, Longy M, Jouary T, et al. Primary cutaneous T-cell lymphomas do not show specific NAV3 gene deletion or translocation. J Invest Dermatol 2008; 128: 2458-2466.
15. Coy JF, Wiemann S, Bechmann I, Bächner D, Nitsch R, Kretz O, et al. Pore membrane and/or filament interacting like protein 1 (POMFIL1) is predominantly expressed in the nervous system and encodes different protein isoforms. Gene 2002; 290: 73-94.
16. Maes T, Barceló A, Buesa C. Neuron navigator: a human gene family with homology to unc-53, a cell guidance gene from Caenorhabditis elegans. Genomics 2002; 80: 21-30.
17. Soon PS, Gill AJ, Benn DE, Clarkson A, Robinson BG, McDonald KL, et al. Microarray gene expression and immunohistochemistry analyses of adrenocortical tumours identify IGF2 and KI-67 as useful in differentiating carcinomas from adenomas. Endocr Relat Cancer 2009; 16: 573-583.
18. Bleeker F, Lamba S, Rodolfo M, Scarpa A, Leenstra S, Vandertop WP, et al. Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes. Human Mutation 2008; 29: 451-459.
19. Wood L, Parson DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113.
20. Hahtola S, Bughart S, Puputti M, Karenko L, Abdel-Rahman WM, Väkevä L, et al. Cutaneous T-cell lymphoma-associated lung cancers show chromosomal aberrations differing from primary lung cancer. Genes Chromosomes Cancer 2008; 47: 107-117.
21. Krohn K, Ranki A, Carlsson E, Ovaska K, Häyry V, Hautaniemi S. WO/2010/046530, Methods and uses involving genetic aberrations of nav3 and aberrant expression of multiple genes [cited 2010 April 29]. Available from: http://www.wipo.int/pctdb/en/wo.jsp?WO=2010046530.
22. Assaf C, Bagot M, Dummer R, Duvic MR, Gniadecki R, Knobler R, et al. Minimising adverse side effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol 2006; 155: 261-266.
23. Kawai K, Uchida Y, Yonekura K, Virtanen S, Tähtinen M, Krohn K, et al. Cutaneous-type adult T-cell leukemia/lymphoma does not primarily show deletion of NAV3 gene. J Invest Dermatol 2010; 130: 316-318.
24. Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113
25. Nord H, Hartmann C, Andersson R, Menzel U, Pfeifer S, Piotrowski A, et al. Characterization of novel and complex genomic aberrations in glioblastoma using a 32K BAC array. Neuro Oncol 2009; 11: 803-818.
26. Bagot M, Nikolova M, Schirm-Chabanette F, Wechsler J, Boumsell L, et al. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann N Y Acad Sci 2001; 941: 31-38.
27. Vermeer MH, van Doorn R, Dukers D, Bekkenk MW, Meijer CJ, Willemze R. CD8+ T cells in cutaneous T-cell lymphoma: expression of cytotoxic proteins, Fas Ligand, and killing inhibitory receptors and their relationship with clinical behavior. J Clin Oncol 2001; 19: 4322-4329.
28. Winter D, Fiebiger E, Meraner P, Auer H, Brna C, Strohal R, et al. Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma. J Immunol 2003; 171: 2714-2724.
29. Forgber M, Gellrich S, Sharav T, Sterry W, Walden P. Proteome-based analysis of serologically defined tumorassociated antigens in cutaneous lymphoma. PLoS One 2009; 4: e8376.
30. van Haren J, Draegestein K, Keijzer N, Abrahams JP, Grosveld F, Peeters PJ, et al. Mammalian navigators are microtubule plus-end tracking proteins that can reorganize the cytoskeleton to induce neurite-like extensions. Cell Motil Cytoskeleton 2009; 66: 824-838.
31. Adamson AS, Collins K, Laurence A, O'Shea JJ. The current STATus of lymphocyte signaling: new roles for old players. Curr Opin Immunol 2009; 21: 161-166.
32. Doherty SD, Ni X, Doherty CB, Jones D, Zhao X, Owen LB, et al. Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions. Arch Dermatol Res 2006; 298: 353-356.
33. Xiao S, Jin H, Korn T, Liu SM, Oukka M, Lim B, et al. Retinoic acid increases Foxp3+ regulatory T cells and inhibits development of Th17 cells by enhancing TGF-beta-driven Smad3 signaling and inhibiting IL-6 and IL-23 receptor expression. J Immunol 2008; 181: 2277-2284.